88 related articles for article (PubMed ID: 20393027)
1. Front-line bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial.
Karihtala P; Mäenpää J; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2010 Mar; 30(3):1001-6. PubMed ID: 20393027
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
Van Cutsem E; de Haas S; Kang YK; Ohtsu A; Tebbutt NC; Ming Xu J; Peng Yong W; Langer B; Delmar P; Scherer SJ; Shah MA
J Clin Oncol; 2012 Jun; 30(17):2119-27. PubMed ID: 22565005
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Penson RT; Dizon DS; Cannistra SA; Roche MR; Krasner CN; Berlin ST; Horowitz NS; Disilvestro PA; Matulonis UA; Lee H; King MA; Campos SM
J Clin Oncol; 2010 Jan; 28(1):154-9. PubMed ID: 19917843
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer.
Zhang L; Zhou Q
Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681
[TBL] [Abstract][Full Text] [Related]
7. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
[TBL] [Abstract][Full Text] [Related]
8. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
Rauvala M; Turpeenniemi-Hujanen T; Puistola U
Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation.
Fountzilas G; Kourea HP; Bobos M; Televantou D; Kotoula V; Papadimitriou C; Papazisis KT; Timotheadou E; Efstratiou I; Koutras A; Pentheroudakis G; Christodoulou C; Aravantinos G; Miliaras D; Petraki K; Papandreou CN; Papakostas P; Bafaloukos D; Repana D; Razis E; Pectasides D; Dimopoulos AM
Anticancer Res; 2011 Sep; 31(9):3007-18. PubMed ID: 21868552
[TBL] [Abstract][Full Text] [Related]
12. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
[TBL] [Abstract][Full Text] [Related]
13. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Apr; 117(1):109-16. PubMed ID: 20056267
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma.
Xiang ZL; Zeng ZC; Fan J; Tang ZY; Zeng HY; Gao DM
Clin Cancer Res; 2011 Aug; 17(16):5463-72. PubMed ID: 21712445
[TBL] [Abstract][Full Text] [Related]
16. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
[TBL] [Abstract][Full Text] [Related]
17. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
19. MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer.
Hiura K; Shiraishi A; Suzuki C; Takamura K; Yamamoto M; Komori H; Watanabe Y; Iwaki-Egawa S
Cancer Biomark; 2015; 15(4):433-40. PubMed ID: 25835177
[TBL] [Abstract][Full Text] [Related]
20. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]